Comparative Pharmacology
Head-to-head clinical analysis: AGGRASTAT versus PYRIDAMAL 100.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AGGRASTAT versus PYRIDAMAL 100.
AGGRASTAT vs PYRIDAMAL 100
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tirofiban is a reversible antagonist of glycoprotein IIb/IIIa receptor, inhibiting platelet aggregation by blocking fibrinogen binding.
Dipyridamole inhibits platelet phosphodiesterase, reducing platelet aggregation; also inhibits adenosine deaminase and increases extracellular adenosine, leading to vasodilation.
A loading dose of 25 mcg/kg administered intravenously over 3 minutes, followed by a maintenance infusion of 0.15 mcg/kg/min for up to 18 hours. For patients with severe renal impairment (GFR <30 mL/min), the maintenance infusion rate is reduced to 0.075 mcg/kg/min.
100 mg orally three times daily.
None Documented
None Documented
Terminal half-life: ~2 hours; clinical context: requires continuous IV infusion for sustained antiplatelet effect
Terminal half-life 10-12 hours; clinical context: steady state achieved in 3-5 days; renal impairment prolongs half-life
Renal: 65% unchanged drug; biliary/fecal: minimal (<5%)
Renal: 50-70% unchanged; biliary/fecal: 20-30% as metabolites; total renal elimination ~85%
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent